Executive interview – VolitionRX reports their Full Year 2017 Earnings

Published on 2 March 2018
 

VolitionRx Limited (VNRX:US), a multi-national life sciences company developing simple, easy to use blood-based cancer tests, today announced its Full Year 2017 earnings and will discuss this news as well as a business update on a conference call this morning. The company this week also announced interim results from a 680-Subject Clinical Trial in Colorectal Cancer.

Share this with friends and colleagues